Fundraising Fox
🦊/Companies
Sign in

Eccogene

Cambridge, US · Founded 2018 · 32 employees on LinkedIn · 9 known investors

Find your way into Eccogene

341 people in our graph share verified history with the Eccogene team — schools, employers, funds. One of them is your warm intro.

Sam Blackmanunlockedknows Jingye Zhou · together at GlaxoSmithKline (overlapped)
×3knows the team · via GlaxoSmithKline
×6knows the team · via Brandeis University
×2knows the team · via Fudan University

Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory conditions, including obesity, type 2 diabetes, and liver disease. Its pipeline includes GLP-1 receptor agonist, THR-β, and SSAO programs, with its lead asset ECC5004 licensed to AstraZeneca.

BiotechHealthtech

Founders & leadership

Eccogene was founded in 2018 by Jingye Zhou.

JZJingye Zhou
Jingye ZhouinCo-founder and CEOJingye Zhou is the founder of Eccogene, a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory conditions. He has spent decades in small molecule drug discovery with expertise in metabolic diseases, immune metabolism, and cancer metabolism.

Investors · 9

Delos CapitalCambridge
New Alliance Capitalreported · 2 sourcesShanghai

Also in the syndicate · 7

Elikon VentureHuajin CapitalOriza Seed CapitalQingsong CapitalRockbleu CapitalYuFu InvestmentZhangjiang Healthcare Venture Capitallead

Funding

SEC filings, press & company announcements
  • Undisclosed amountSeries BJun 2023

    New Alliance Capital (lead), Zhangjiang Healthcare Venture Capital (lead), Delos Capital, Elikon Venture, Huajin Capital, Oriza Seed Capital, Qingsong Capital, Rockbleu Capital, YuFu Investment

    Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

In the news

Eccogene Receives Milestone Payment of $60 Million from AstraZeneca Following Dosing of the First Patient in Global Phase 2b Program of ECC5004/AZD5004 for the Treatment of Obesity and Type 2 Diabetesglobenewswire.com · Oct 2024AstraZeneca pays $185M upfront to reenter oral obesity gold rush, drops phase 2 sickle cell drugfiercebiotech.com · Nov 2023AstraZeneca raises stakes in obesity drug race with Eccogene deal | Reutersreuters.com · Nov 2023UPDATE 3-AstraZeneca raises stakes in obesity drug race with Eccogene dealfinance.yahoo.com · Nov 2023China Digest: Eccogene, UDS, Emposat snap fundingdealstreetasia.com · Jun 2023Eccogene Raises CNY 180 Million in Series B Equity Financing, Propelling its Pipeline of Treatments for Metabolic Diseases | Delos Capitaldeloscapital.com · Jun 2023

Frequently asked questions

What does Eccogene do?
Eccogene is a clinical-stage biopharmaceutical company developing oral small molecule therapeutics for cardiometabolic and inflammatory conditions, including obesity, type 2 diabetes, and liver disease. Its pipeline includes GLP-1 receptor agonist, THR-β, and SSAO programs, with its lead asset ECC5004 licensed to AstraZeneca.
Who founded Eccogene?
Eccogene was founded by Jingye Zhou in 2018.
Who are Eccogene's investors?
Eccogene's investors include Delos Capital, New Alliance Capital.
Where is Eccogene headquartered?
Eccogene is headquartered in Cambridge, US.